Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Antimicrobial Resistance Market size was valued at USD 8.6 billion in 2024 and is estimated to reach USD 19.1 billion by the end of 2037, expanding at a CAGR of 7.3% during the forecast period from, 2025-2037. In 2025, the industry size of antimicrobial resistance is expected to reach USD 9.2 billion.
The patient pool in the antimicrobial resistance market is readily expanding, with an estimated 2.9 billion yearly infection occurrences solely in the U.S., and approximately 11 million deaths are projected internationally by the end of 2050. For instance, hospital-acquired infections (HAIs) cater for almost 37% of AMR cases, which is effectively driving the need for rapid novel therapeutics and diagnostics. Besides, the supply chain system for AMR products, including diagnostic devices, finished drugs, and active pharmaceutical ingredients (APIs), is gaining exposure, especially from key manufacturing centers in China, accounting for 45% of the worldwide antibiotic supply, thus suitable for the market upliftment.
Furthermore, the aspect of economic indicators has revealed a surge in costs for market mitigation. In this regard, the producer price index for antibiotics has surged by 13% between 2022 and 2024, highly facilitated by strict good manufacturing practice (GMP) compliance, along with inflation in the supply chain. Likewise, the consumer price index has risen by almost 8.4% for hospital AMR treatment services, facilitating high drug expenses and diagnostics. Besides, governments from all across nations are effectively funding, particularly to conduct research, development, and deployment, with the U.S. BARDA providing USD 1.3 billion for AMR clinical studies, thereby driving the market expansion.
Antimicrobial Resistance Sector: Growth Drivers and Challenges
Growth Drivers
- Cost saving and improvement in health quality: The aspect of innovation in medical and healthcare settings is denoting continuous modifications and improvements, which are positively impacting the market internationally. As per a clinical study conducted by the AHRQ in 2022, early intervention can tend to diminish hospitalizations by approximately 25%, resulting in a saving of USD 2.1 billion for almost two years. Besides, the antibiotic resistance surveillance system in Germany successfully reduced redundant prescriptions by 32%, while the Netherlands combated ICU AMR deaths by nearly 15.5%, thus enhancing the market exposure.
- Organization innovation and strategies: The existence of conventional exit from antibiotics across pharmaceutical firms is reversing, which is readily driving the market globally. This has been possible with GSK’s gepotidacin, which is the first-ever novel oral antibiotic within 20 years, along with Pfizer’s USD 355 million BARDA partnership. Besides, startup firms, including Entasis and Nabriva, are effectively concentrating on narrow-spectrum antibiotics, and Roche’s 30-minute diagnostic captured an estimated 16.5% of the EU market, all of which caters to an optimistic outlook for the market.
Manufacturer Strategies Shaping the Antimicrobial Resistance Market Expansion
Leading manufacturers and producers in the market are implementing three essential initiatives to expand their positions in the global market arena. These include niche product innovation, expansion in developing nations, and public-private partnerships. For instance, GSK has effectively targeted almost 22 million patients in India to leverage a tiered pricing strategy to enhance accessibility. Likewise, Pfizer’s collaborative strategy resulted in accelerating research and development activities for antibiotics, ultimately leading to diminished development difficulties, thus suitable for market upliftment.
Revenue Opportunities for AMR Manufacturers (2023-2025)
|
Company |
Strategy |
Revenue Impact (2023-2025) |
|
Pfizer |
BARDA-funded antibiotics |
+USD 488 million |
|
Roche |
Rapid AMR diagnostics |
+USD 230 million (EU sales) |
|
GSK |
Gepotidacin (UTI focus) |
+USD 325 million (India expansion) |
|
Merck |
CARB-X antibiotic grants |
+ USD 210 million (Phase 3 trials) |
|
bioMérieux |
AI-driven AST systems |
+USD 180 million (US hospitals) |
Feasible Expansion Models Shaping the Future AMR Market
The market is continuously evolving through the adoption of three precise and scalable models, including diagnostic-first stewardship, tiered pricing, and private-public collaborations. For instance, there have been partnerships between suppliers and state hospitals in India, which increased revenue by almost 12.5% by aligning with the National Action Plan. Besides, Medicare effectively bundled payments in the U.S. to ensure rapid AMR evaluations that drove USD 250 million in manufacturer revenue. Therefore, all these models critically addressed barriers, accounting for 42% of hospital diagnostics across developing countries, thereby boosting the market growth.
Feasibility Models for AMR Market Expansion (2022-2024)
|
Model |
Region |
Revenue Impact |
|
Hospital Partnerships |
India |
+12.5% revenue growth |
|
Tiered Pricing |
Africa |
8.3% market share capture |
|
Medicare Bundled Payments |
U.S. |
USD 250 million manufacturer revenue |
Challenges
- Barriers in reimbursements and pricing: The antimicrobial resistance market is subject to undergo pressure, owing to a lack of reimbursement models and strict government cost models. For instance, in Europe, there is the presence of stringent price caps, such as Germany’s AMNOG law, which has slashed antibiotic prices by an estimated 18% in 2023, and forced organizations, including Pfizer, to implement value-based contracts tied to patient outcomes. Besides, Medicaid in the U.S. provides only 35% coverage for novel AMR drugs, owing to a surge in overall costs, leading to exposed populations being underserved, thereby affecting the market.
- Delayed approvals: The aspect of inconsistent and lengthy acceptance processes readily hinders the overall market development internationally. For instance, the Limited Population Pathway of the FDA has accepted only 5 AMR drugs since 2020, despite an urgent requirement. Besides, administrative divergence across nations pressurizes manufacturers to replace trials, which has bolstered costs by USD 55 million per drug. Meanwhile, poorly harmonized guidelines result in further delays in advancements, thereby causing a hindrance in the market and expansion across different countries.
Antimicrobial Resistance Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.3% |
|
Base Year Market Size (2024) |
USD 8.6 billion |
|
Forecast Year Market Size (2037) |
USD 19.1 billion |
|
Regional Scope |
|
Antimicrobial Resistance Segmentation
Drug Class (Antibiotics, Antivirals, Antifungals, Antiparasitics)
Based on drug class, the antibiotics segment is projected to hold the largest share of 45.8% in the antimicrobial resistance market by the end of 2037. The segment’s growth is effectively attributed to urgent clinical demands, along with escalated bacterial resistance. In addition, standard government interventions, such as the DISARM Act in the U.S., have improved reimbursement models and transferable exclusivity vouchers in the EU. Besides, beta-lactams under the segment caters to more than 65% of antibiotic demand, owing to their efficacy against pathogens, such as ESBL and MRSA-producing Enterobacteriaceae, thereby driving the overall market.
Pathogen (Bacteria, Virus, Fungi, Parasites)
Based on pathogen, the bacteria segment is anticipated to hold the second-largest share of 42.7% in the antimicrobial resistance market during the forecast timeline. This has effectively reflected the segment’s status as the most essential antimicrobial resistance threat. Gram-negative bacteria, especially ESBL-producing E. coli and Pseudomonas aeruginosa, collectively drive an estimated 66.5% of bacterial AMR expenses, due to high mortality rates and rapid resistance development. Besides, HAIs also constitute 74% of bacterial AMR cases, with ventilator-associated pneumonia and surgical site infections creating enhanced treatment spending, thus positively impacting the segment.
Our in-depth analysis of the antimicrobial resistance market includes the following segments:
|
Drug Class |
|
|
Pathogen |
|
|
End User |
|
|
Diagnostic Type |
|
|
Distribution |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportAntimicrobial Resistance Industry - Regional Synopsis
North America Market Analysis
North America in the market is anticipated to dominate with a share of 48.5% by the end of 2037. This dominance is possible with the U.S., majorly accounting for approximately 84% of the overall regional market. This, however, is possible with factors, including the presence of provincial investments, rapid diagnostics solutions, expansion in Medicare services, and the allocation of federal funding. For instance, as per an article published by HHS, an estimated USD 5.5 billion has been funded in 2023 for developing the market in the region. Likewise, Medicare provides USD 850 million for AMR expenditure in 2023, thus enhancing the market exposure.
The antimicrobial resistance market in the U.S. is significantly propelling, facilitated by bundling payment options for rapid diagnostics by Medicare and a rise in CRE infections. Besides, the DISARM Act has successfully incentivized antibiotic development with USD 3.8 billion in funding, due to which there has been market progress in the country. Meanwhile, approximately 55% of hospitals in the country currently utilize genomic resistance tracking, denoting innovations in the market. Therefore, all these factors are in favor of market upliftment, due to which there is more exposure in the country.
The antimicrobial resistance market in Canada is gaining increased traction, owing to the presence and existence of provincial stewardship, with BC diminishing farm antibiotic utilization by almost 27.5%. Besides, the PHAC’s strategy of investing USD 1.9 billion by the end of 2037 readily targets diagnostic expansion in rural clinic facilities. In addition, almost 42% of hospitals are devoid of rapid evaluation services, thereby driving the USD 505 million federal investment. Meanwhile, indigenous communities in the country experience high AMR rates, which has prompted a USD 205 million equity initiative, thus driving market growth.
Europe Market Statistics
Europe in the antimicrobial resistance market is expected to account for the fastest-growing region with a share of 32.7% during the forecast timeline. The market’s growth in the region is effectively fueled by an increase in healthcare spending and the existence of strict stewardship reforms. Besides, the €2.7 billion AMR action fund in the EU has readily accelerated the antibiotic development, while the UK and Germany are deliberately leading in diagnostic implementation, wherein 74% of hospitals are rapidly utilizing AST tests, thereby creating a positive outlook in the overall region.
The antimicrobial resistance market in Germany is projected to dominate the overall region with a 32.5% revenue share by the end of 2037. This dominance is highly attributed to manufacturing capabilities as well as robust diagnostic infrastructure. Additionally, more than 71% of hospitals in the country presently deploy speedy antimicrobial susceptibility testing (AST) systems, ultimately leading to lowered detection times by 95%. Besides, the €520 million AMR research fund by the government effectively supports notable antibiotics, while regional API manufacturing combats supply chain challenges, thus suitable for market upliftment.
The antimicrobial resistance market in the UK is gradually propelling, and is expected to hold almost 28.5% of the regional market share by the end of the forecast duration. This growth is effectively facilitated by progressions in surveillance and financing. For instance, as per the 2024 DHSC report, the NHS subscription model has guaranteed £12 million per year for prioritized antibiotics that tend to increase manufacturing participation by 41.5%. Besides, genomic surveillance covers 52% of hospital-onset infections, further enabling targeted interventions, thus constituting a positive impact on the market.
Companies Dominating the Antimicrobial Resistance Landscape
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The global market is extremely fragmented, with the presence of organizations, including GSK, Merck, and Pfizer, effectively leading through diagnostic integration, along with public-private partnerships. Besides, bioMérieux and Roche readily dominate rapid evaluation, while generic makers in India, including Lupin and Cipla, cater to affordability barriers. Meanwhile, Shionogi is deliberately leading in Japan with PDMA-based advancements, which are positively impacting the overall market expansion and upliftment across different nations. The aspect of stewardship technology, API onshoring, along with pull incentives, are other relevant drivers, bolstering the market exposure internationally.
Here is a list of key players operating in the global market:
|
Company Name (Country) |
Industry Focus |
Market Share (2024) |
|
Pfizer Inc. (U.S.) |
Novel antibiotics (e.g., Zavicefta), AMR diagnostics, and public-private partnerships. |
14% |
|
Merck & Co. (U.S.) |
CARB-X-funded antibiotics (e.g., relebactam), rapid diagnostics, and stewardship programs. |
11% |
|
GlaxoSmithKline (GSK) (UK) |
Beta-lactam antibiotics (e.g., gepotidacin), vaccines for resistant pathogens. |
10% |
|
Roche Diagnostics (Switzerland) |
AI-powered rapid AST systems (e.g., Cobas), PCR-based AMR detection. |
9% |
|
Novartis AG (Switzerland) |
Narrow-spectrum antibiotics, antifungal R&D (e.g., FIC antifungal pipeline). |
8% |
|
Abbott Laboratories (U.S.) |
Point-of-care AMR diagnostics (e.g., ID NOW), antimicrobial stewardship tools. |
xx% |
|
Johnson & Johnson (U.S.) |
TB/MDR-TB therapeutics (e.g., bedaquiline), phage therapy research. |
xx% |
|
Sanofi (France) |
Antibiotic combinations (e.g., sulbactam-durlobactam), LMIC access programs. |
xx% |
|
AstraZeneca (UK) |
Beta-lactamase inhibitors (e.g., aztreonam-avibactam), AMR vaccine development. |
xx% |
|
Bayer AG (Germany) |
Veterinary AMR solutions, antibiotic alternatives for livestock. |
xx% |
|
bioMérieux SA (France) |
Automated AST systems (e.g., VITEK), WHO-prequalified AMR diagnostics. |
xx% |
|
Thermo Fisher Scientific (U.S.) |
Genomic AMR surveillance (e.g., Ion Torrent), culture media for resistant pathogens. |
xx% |
|
Cipla Ltd. (India) |
Affordable generics (e.g., colistin), AMR-focused manufacturing for LMICs. |
xx% |
|
Lupin Limited (India) |
API production for carbapenems, AMR stewardship collaborations. |
xx% |
|
CSL Limited (Australia) |
Immunotherapies for resistant infections, plasma-derived antimicrobials. |
xx% |
Below are the areas covered for each company in the market:
Recent Developments
- In June 2024, Roche Diagnostics launched Cobas AMR Direct, which is a 30-minute PCR evaluation and CR-certified test that can detect CRE and ESBL infections, and is readily integrated in hospital EHRs for real-time stewardship notifications.
- In May 2024, Pfizer Inc. achieved the FDA Fast Track designation for its notable PF-07304814 antibiotic, which can readily target Acinetobacter baumannii, which is a multidrug-resistant.
Author Credits: Radhika Pawar
- Report ID: 7720
- Published Date: Jun 06, 2025
- Report Format: PDF, PPT
